Wall Street Zen lowered shares of Insulet (NASDAQ:PODD – Free Report) from a buy rating to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.
Several other analysts have also recently weighed in on PODD. TD Cowen cut their price objective on Insulet from $294.00 to $144.00 and set a “hold” rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $152.00 target price (down from $275.00) on shares of Insulet in a research report on Thursday, August 6th. Barclays raised Insulet to a “hold” rating in a research report on Wednesday, October 7th. Oppenheimer cut Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, Jefferies Financial Group dropped their price target on Insulet from $275.00 to $190.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $186.68.
View Our Latest Research Report on Insulet
Insulet Trading Up 0.2%
NASDAQ:PODD opened at $149.26 on Friday. The company has a 50-day moving average price of $140.62 and a 200-day moving average price of $182.66. The stock has a market cap of $10.35 billion, a price-to-earnings ratio of 27.90, a P/E/G ratio of 1.17 and a beta of 1.11. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88.
Insulet (NASDAQ:PODD – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. During the same quarter in the previous year, the company earned $1.17 earnings per share. Insulet’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities analysts predict that Insulet will post 6.51 EPS for the current year.
Institutional Investors Weigh In On Insulet
Institutional investors have recently made changes to their positions in the company. SYM FINANCIAL Corp bought a new stake in Insulet in the 3rd quarter worth about $323,000. Apollon Wealth Management LLC raised its position in Insulet by 10.7% in the 3rd quarter. Apollon Wealth Management LLC now owns 2,514 shares of the medical instruments supplier’s stock worth $328,000 after buying an additional 242 shares during the last quarter. Citizens Financial Group Inc. RI raised its position in Insulet by 138.0% in the 3rd quarter. Citizens Financial Group Inc. RI now owns 7,880 shares of the medical instruments supplier’s stock worth $1,028,000 after buying an additional 4,569 shares during the last quarter. Inspire Investing LLC lifted its stake in Insulet by 2.6% during the 3rd quarter. Inspire Investing LLC now owns 6,792 shares of the medical instruments supplier’s stock valued at $886,000 after acquiring an additional 174 shares during the period. Finally, Yousif Capital Management LLC lifted its stake in Insulet by 2.4% during the 3rd quarter. Yousif Capital Management LLC now owns 9,484 shares of the medical instruments supplier’s stock valued at $1,237,000 after acquiring an additional 219 shares during the period.
Insulet Company Profile
Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.
Recommended Stories
- Five stocks we like better than Insulet
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
